An interventional study of NightWare and Sham NightWare in Post Traumatic Stress Disorder, Cardiovascular Diseases and Autonomic Dysfunction, sponsored by University of Colorado, Denver. Recruiting at 2 sites in United States. Open to female participants aged 22 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Stress Disorders, Post-Traumatic by University of Colorado, Denver — 4 open to participants now, 4 under way, none of them phase 3. Stress Disorders, Post-Traumatic · University of Colorado, Denver.
Among the 13 studies in Stress Disorders, Post-Traumatic by University of Colorado, Denver, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2025, is one of 10 with no phase, and was the 13th registered.
2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →4 of the 13 studies in Stress Disorders, Post-Traumatic by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
University of Colorado, Denver · Sites in United States
Ages 18–85 · Healthy volunteers
By country, each count listing its studies:
Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.
This study: 22 Years to 40 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 69 across 2,203 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 57 across the 12 interventional studies, 330 across the 1 observational. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Stress Disorders, Post-Traumatic by University of Colorado, Denver, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether NightWare therapeutic intervention improves biomarkers of vascular and renal function in premenopausal women with PTSD-related nightmares, and examine whether these improvements restore them to levels observed in age-matched women without PTSD.
Women are disproportionally affected by posttraumatic stress disorder (PTSD), a debilitating mental health disorder that profoundly increases cardiovascular disease (CVD) risk. Biological processes including vascular dysfunction (i.e., impaired endothelial function, arterial stiffening), increased renin-angiotensin-aldosterone system (RAAS) activity, and altered renal vascular control and function may contribute to the pathophysiological link between PTSD and CVD. Sleep is a key regulator of cellular and tissue repair, free radical detoxification, oxidative stress, inflammation, autonomic and endocrine balance and crucial for cardiovascular health. Sleep disturbances due to nightmares are a hallmark symptom of PTSD that cause significant distress and may independently contribute to elevated CVD risk in individuals with PTSD. As such, interventions aimed at treating trauma-related nightmares are a promising therapeutic approach in ameliorating the cardiovascular consequences of PTSD.
NightWare™, a smart-watch based application that uses biometric data and vibrotactile feedback to disrupt nightmares, is an FDA approved digital therapeutic system for the treatment of nightmares in adults (≥22 years) with PTSD. While a preliminary study demonstrated that 30 days of NightWare treatment improved subjective sleep quality in Veterans, the influence of NightWare treatment on vascular and renal function in young women with PTSD-related nightmares is unknown. These investigations are critical among women who, despite having 2x greater prevalence of PTSD compared to men, and a differential progression of PTSD, CVD, and chronic kidney disease (CKD), are underrepresented in the literature.
Accordingly, the investigators will examine if the NightWare digital therapeutic system improves vascular and renal function in premenopausal women with PTSD-related nightmares, and whether these improvements restore them to levels observed in age-matched women without PTSD. We will employ 1) cross-sectional comparisons between two groups of women: those with PTSD and nightmares (PTSD group) and those without PTSD and nightmares (age-matched control group); and 2) a short-term (8-week) NightWare or sham intervention in women with nightmares related to PTSD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In women with PTSD-related nightmares randomized to the active condition, when the stress index is reached during sleep, NightWare will intervene with varying degrees of vibratory stimulation to the watch over a variable length of time to arouse the person out of the nightmare without awakening.
Device: NightWare
In women with PTSD-related nightmares randomized to the sham condition, the NightWare intervention will not be enabled
Device: Sham NightWare
Age-matched women without PTSD-related nightmares will complete baseline testing only (no intervention).
A wearable digital therapeutic platform consisting of an Apple Watch and iPhone pre-provisioned with Nightware intervention app that will deliver a mild vibration to the watch after detecting individual having a nightmare based on Nightware proprietary algorithm, arousing the individual and disrupting nightmare without awakening.
NightWare decive will not deliver an intervention (i.e., no vibration)
Brachial artery flow-mediated dilation (FMD)
FMD of the brachial artery, calculated as a percentage, is an index of vascular function. A higher number is a general indicator of better vascular function.
Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
Large artery elastic stiffness
Carotid-femoral pulse wave velocity (PWV). A higher number is a general indicator of worse vascular function.
Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
Large artery elastic stiffness-carotid artery
Carotid artery compliance using carotid artery ultrasound; a higher carotid artery compliance is a general indicator of better vascular function.
Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
Autonomic function-baroreflex sensitivity
Cardiovagal baroreflex sensitivity (cBRS) measured using beat-to-beat time series of systolic blood pressures (finger photo-plethysmography) and R-R interval (three-lead electrocardiogram) will be recorded simultaneously at 1,000 Hz.
Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
Autonomic function- heart rate variability
Heart rate variability
Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
Blood pressure
Seated blood pressure measured in mmHg
Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
Estimated glomerular filtration rate (eGFR)
Serum cystatin C, alongside demographic information, will be used to estimate kidney filtration of waste and excess water. A low eGFR can indicate renal dysfunction.
Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
Renal vascular control
Peak change in renal vascular resistance in response to sympathoexcitation via cold pressor test
Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
Renal functional reserve
Peak change in creatinine clearance (calculated using urine creatinine, serum creatinine, urine flow rate) following ingestion of oral protein
Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
Pittsburgh Sleep Quality Index (PSQI)
Sleep questionnaire with a scale of 0 to 21 with a higher score indicating a significant sleep disturbance
Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
Pittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A)
Sleep questionnaire to assess frequency of seven disruptive nocturnal behaviors; scores range from 0-21 with higher scores indicating more severe PTSD-related sleep disturbances.
Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
PTSD Checklist for DSM-5 (PCL-5)
Presence and severity of PTSD symptoms questionnaire; scores range from 0-80 with higher scores indicating more severe PTSD symptoms.
Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
Nightmare Disorder Index (NDI)
5-item questionnaire related to nightmares; scores range from 0-20 with higher score indicates more severe nightmare symptoms.
Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
Columbia Suicide Severity Rating Scale (CSSR-S)
Questionnaire used for suicide risk assessment; categorizes level of suicide risk (low, moderate, high) based on responses to questions about suicidal ideation and behavior.
Time frame: PTSD vs controls at baseline. In PTSD group only, change with NightWare vs Sham (measured pre and post-intervention 8 weeks of NightWare or sham conditions).
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Jul 2028, 35 months after the start.
Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 35 months is close to that.
Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.
Start moved once since we started tracking on Sep 25, 2026: Jul 2025 → Aug 2025, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stress Disorders, Post-Traumatic →
University of Colorado, Denver →